Health
Cancer Prevention
2015 IPO

Interpace Diagnostics

$0.806
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0132 (-1.55%) Today
-$0.0308 (-3.68%) As of 4:30 PM EDT after-hours

Why Robinhood?

You can buy or sell IDXG and other stocks, options, ETFs, and crypto commission-free!

About IDXG

Interpace Diagnostics Group, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. Read More The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.

Employees
89
Headquarters
Parsippany, New Jersey
Founded
1986
Market Cap
31.86M
Price-Earnings Ratio
Dividend Yield
Average Volume
261.89K
High Today
$0.8478
Low Today
$0.80
Open Price
$0.8288
Volume
152.37K
52 Week High
$1.78
52 Week Low
$0.6727

Collections

Health
Cancer Prevention
2015 IPO
US
North America

IDXG News

BenzingaJul 15

Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business Supported by Investment from Ampersand Capital Partners

76
Seeking AlphaJun 20

Health insurer to cover Interpace Diagnostics cancer tests

461

IDXG Earnings

-$0.11
-$0.09
-$0.08
-$0.06
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours

More IDXG News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.